IFNL3Your two copies: rs12979860C/rs12979860T
CTUnfavorable response genotype
An immune gene that affects how well hepatitis C treatment works.
This result changes the label.
Example report. The whole genome example: a public genome from the 1000 Genomes Project, with CYP2D6 Structural Analysis, so you can see what yours will look like. Get your own report
Antivirals · AntiviralsExample report
Peginterferon Alfa-2A
Pegasys
Consider alternative
This hepatitis C drug is less likely to clear the virus for people with your genes. Your doctor may consider a different treatment.
The genes behind this label
The guidelines read one gene for peginterferon alfa-2a. Each card shows the two copies this person inherited and what they mean.
What the guidelines say
What each guideline says about your result.
IFNL3Unfavorable response genotype
CPIC guideline
Evidence: strongRead the guideline (Clinical Pharmacogenetics Implementation Consortium, opens in a new tab)
- In plain words
- This hepatitis C drug is less likely to clear the virus for people with your genes. Your doctor may consider a different treatment.
- What it means
- Approximately 30% chance for sustained virologic response (SVR) after 48 weeks of treatment. Consider implications before initiating PEG-IFN alpha and RBV containing regimens.
- What the guideline suggests
- Approximately 60% chance for SVR after 24-48 weeks of treatment. Approximately 50% of patients are eligible for shortened therapy (24-28 weeks). Consider implications before initiating PEG-IFN alpha and RBV containing regimens.
About peginterferon alfa-2a
Peginterferon alfa-2a (Pegasys) is a long-acting interferon injection that was a backbone of hepatitis C treatment, given with ribavirin for 24 to 48 weeks.
- Used for
- Chronic hepatitis C (with other antivirals) and chronic hepatitis B
Others in antivirals
Compare all 5 antiviralsDon't change a dose on your own. Bring this report to your prescriber or pharmacist. They can weigh it with everything else they know about you.